Target intelligence / Profile preview

Ribonuclease pancreatic (RNase 1)

Target
RNase 1
Molecular classification
Enzyme, Secretory endoribonuclease, Ribonuclease A superfamily
01

Overview

Ribonuclease pancreatic (RNase 1) is a secretory endoribonuclease enzyme encoded by the human RNASE1 gene. It is a member of the ribonuclease A superfamily and catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides, with a preference for poly(C) substrates. Unlike related digestive homologs, human RNase 1 is widely expressed in many tissues and is found at remarkable concentrations in the blood and other biological fluids. It degrades both single- and double-stranded RNA and plays roles beyond digestion, particularly in regulating extracellular RNA in processes such as blood coagulation, inflammation, and innate immunity. The protein is monomeric, may be glycosylated at specific sites, and interacts with cell-surface glycans. Engineered forms of RNase 1 are being developed as anticancer agents. Abnormal serum levels or glycoforms of RNase 1 have been implicated as candidate biomarkers in certain cancers[1][2][3][5].

Other names
Ribonuclease A family member 1, pancreaticRNASE1RNase ARIB1RNS1RAC1HP-RNaseRIB-1RNase UpI-1Ribonuclease 1Ribonuclease A C1ribonuclease pancreaticribonuclease, RNase A family, 1 (pancreatic)
02

Mechanism of action

RNA degradation by endonucleolytic cleavage; Potential antitumor effect via targeted RNA hydrolysis in cancer cells

03

Biological functions

RNA degradationCleavage of internal phosphodiester RNA bonds (endonuclease activity)Regulation of extracellular RNABlood coagulationInflammationImmune response
04

Disease associations

CancerInflammationCardiovascular diseaseOther (implicated in mesothelioma, retinitis pigmentosa)
05

Safety considerations

Targeting RNase 1 systemically may affect normal extracellular RNA balance affecting hemostasis, vascular permeability, and immune functions[2][5]
06

Interacting drugs

None established as standard; engineered forms are in clinical trials as chemotherapeutic agents for cancer[2]
07

Biomarkers

Glycosylated forms of RNase 1 (e.g., serum RNase 1 with N-glycosylated Asn88) have been proposed as biomarkers in pancreatic cancer[2]

Beyond the preview

Go deeper on Ribonuclease pancreatic (RNase 1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribonuclease pancreatic (RNase 1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call